Stratum Biosciences Secures $2M to Decode Skin Secrets with AI

NEW YORK, NY – March 27, 2026 – Stratum Biosciences, a biotechnology startup at the forefront of dermatological research, today announced the successful closing of a $2 million seed funding round. The investment, a significant vote of confidence in the company's pioneering approach, was backed by the Harvard Business School Alumni Angels of Greater New York and Skin Angels, the world's largest network of early-stage dermatology investors.

The capital injection is earmarked to scale Stratum's proprietary SkinSync™ platform, an advanced artificial intelligence system designed to mine a vast proprietary biobank of over 200,000 real human skin samples. The company aims to translate these data-driven discoveries into accelerated development of novel ingredients and formulations, tackling some of the most persistent challenges in skin health.

Founded in 2024 by esteemed dermatologist Dr. Ross Lane Pearlman and dermatopathologist Dr. Buu Duong, Stratum is on a mission to bridge what it sees as the most critical gap in dermatological innovation: a fundamental understanding of skin biology.

"As a dermatologist, I see every day that the biggest gap in skin innovation is our limited understanding of skin biology," said Dr. Ross Pearlman, CEO and Co-founder of Stratum Biosciences. "With modern AI, we can finally uncover the mechanisms hidden within skin that can translate into entirely new solutions to skin health."

A New Paradigm for Skin Discovery

Stratum Biosciences is moving beyond traditional, often slow-paced research and development methods. Instead of relying on conventional models, the company's SkinSync™ platform directly interrogates real human tissue, integrating over 50 clinical and physicochemical variables from more than 7,000 standardized experiments. This deep-dive into real-world biology allows the AI to identify previously unseen patterns, biomarkers, and causal relationships that govern skin health, aging, and disease.

The company’s approach represents a paradigm shift from observational research to actively decoding the skin’s complex biological language. This is made possible by its leadership team, which combines deep clinical expertise with technological vision. Dr. Pearlman is an award-winning dermatologist with over 40 publications, while Dr. Duong brings a wealth of experience in dermatopathology and digital informatics, having previously tripled revenue at his former practice by leading advancements in the field.

"Our skin is a window to our bodies, and Stratum's biobank holds the keys to new, undiscovered targets for anti-aging and beyond," stated Dr. Buu Duong, President and Co-founder. "We now have the tools to unlock these insights and build solutions at scale. Beyond observational research, we are now decoding the skin's biological language to redefine how the industry approaches longevity and health."

The Power of Strategic Partnerships and AI

Central to Stratum's ambitious plan is its participation in NVIDIA's Inception program, a global initiative that nurtures startups revolutionizing industries with technological advancements. Access to NVIDIA's formidable computing resources provides the necessary horsepower for Stratum to rapidly process its massive database, accelerating the identification of novel biomarkers that have long eluded researchers.

This technological prowess is already yielding results. According to the company, the SkinSync™ platform has uncovered significant insights that challenge long-held assumptions about the skin barrier, a critical component in skin health. These findings are foundational for developing new composition-of-matter actives and formulations with optimized bioavailability.

This rapid progress has been overseen by Chief Scientific Officer Dr. David Osborne, a world-renowned expert on topical formulations and a co-founder of Arcutis Biotherapeutics (ARQT). Dr. Osborne, who holds over 40 patents and was instrumental in launching commercially successful drugs like Zoryve™, praised the company's early achievements.

"The scientific progress this team has been able to make in such a short amount of time has been remarkable," said Dr. Osborne. "It's exciting to take my career experience and use the platform and methodology created by Stratum to rewrite our understanding of dermatology and fundamentally improve human skin care."

Investing in a High-Growth Market

The $2 million seed round is not just a lifeline for a promising startup; it is a strategic investment in a rapidly expanding market. The global Dermatology AI market, valued at approximately $712 million in 2024, is projected to surge to over $7.3 billion by 2033. This explosive growth reflects a broader industry trend toward leveraging AI for precision diagnostics and personalized medicine.

Stratum's investors represent a powerful combination of business acumen and scientific validation. The Harvard Business School Alumni Angels of Greater New York is the largest angel network in the metro area, with a strong track record in backing successful tech and life science ventures. Crucially, the participation of Skin Angels, a network composed of scientific and clinical dermatology experts, provides a peerless endorsement of Stratum’s scientific methodology and its potential to disrupt the field.

While many companies focus on using AI for diagnostics and telemedicine, Stratum has carved out a unique niche in fundamental discovery. By focusing on the 'why' behind skin conditions, it aims to create the next generation of solutions rather than just better ways to identify existing problems.

From Incubator to Industry Leader

Stratum Biosciences is currently a resident company at Johnson & Johnson's prestigious JLABs@NYC incubator in SoHo. This residency provides a capital-efficient and resource-rich environment, offering access to state-of-the-art labs, mentorship from Johnson & Johnson experts, and unparalleled networking opportunities within the life sciences ecosystem. Over the past year, Stratum has already leveraged this position to validate its approach, partnering with global CPG leaders to develop novel actives targeting pressing needs like hyperpigmentation and skin longevity.

With this new infusion of capital, Stratum is set to aggressively expand these R&D partnerships, translating its AI-driven discoveries into a pipeline of high-value intellectual property and tangible products. By combining a world-class team, a powerful AI platform, and a unique repository of biological data, the company is poised to redefine the future of skincare and dermatological treatments for years to come.